Source comparison
GHK-Cu vs TB-500: Research Application Comparison
Before examining individual parameters, understand that this comparison reflects outcomes from published research models. Not clinical treatment protocols. Both peptides are sold for research purposes only. Primary Mechanism Copper chelation → MMP modulation →
This comparison does not assign a generated winner or score.
- Before examining individual parameters, understand that this comparison reflects outcomes from published research models. Not clinical treatment protocols. Both peptides are sold for research purposes only.
- Primary Mechanism
- Copper chelation → MMP modulation → collagen synthesis
- G-actin sequestration → cytoskeletal reorganization → cell migration
- Non-overlapping pathways; selection depends on target tissue depth
- Optimal Tissue Target
- Epidermis, superficial dermis, vascular endothelium
- Tendons, ligaments, muscle, cardiac tissue, deep fascia
- GHK-Cu for <2mm depth; TB-500 for systemic and structural tissue
- Administration Route
- Topical (1–2% formulation), subcutaneous (1–2mg/day)
- Subcutaneous or intramuscular injection only (2–5mg twice weekly)
- Topical bioavailability exists only for GHK-Cu
- Half-Life
- ~3 hours (serum), tissue retention 24–48 hours
- ~10 hours (serum), upregulated gene expression persists 72+ hours
- TB-500's longer signaling window suits pulsed dosing protocols
- Collagen Upregulation
- Type I collagen mRNA +70%; Type III collagen +40%
- Minimal direct collagen effect; indirect via fibroblast recruitment
- GHK-Cu directly stimulates collagen genes; TB-500 brings cells to the site
- Angiogenic Effect
- Moderate (VEGF +30% in hypoxic conditions)
- Strong (VEGF +180%, angiopoietin-1 +95%)
- TB-500 dominates vascular remodeling; essential for ischemic injury
- Inflammation Modulation
- Suppresses TNF-α and IL-6; shifts macrophages toward M2 phenotype
- Suppresses NF-κB pathway; reduces neutrophil infiltration by 55%
- Both are anti-inflammatory; TB-500 acts earlier in the cascade
- Research Cost (per study)
- $180–$320 for 4-week protocol (topical or low-dose injection)
- $420–$680 for 4-week protocol (standard 2mg 2x/week dosing)
- Cost scales with molecular weight and synthesis complexity
- The bottom-line assessment: GHK-Cu outperforms TB-500 in research models where the injury is confined to epidermal or superficial dermal layers, particularly when cosmetic outcomes (minimal scarring, pigmentation control) are measured. TB-500 outperforms GHK-Cu when the research question involves deep tissue structures, systemic healing responses, or injuries where inadequate vascularization limits repair. Such as tendon insertions, avascular cartilage interfaces, or ischemic myocardial zones.